Showing 241 - 260 results of 25,187 for search '(( 5 non decrease ) OR ( 50 ((((nn decrease) OR (we decrease))) OR (a decrease)) ))', query time: 0.64s Refine Results
  1. 241

    Phosphorylation as an Effective Tool to Improve Stability and Reduce Toxicity of Antimicrobial Peptides by Zufang Ba (11036420)

    Published 2024
    “…Phosphorylation can reduce toxicity and improve the stability of AMPs. Based on these, we designed a series of peptides and their corresponding phosphorylated forms. …”
  2. 242

    DataSheet_2_A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells.docx by Yu-Ying Shi (15975992)

    Published 2023
    “…Introduction<p>Our previous research has found that degradation of palmitoyltransferase in tumor cells using a linear peptide PROTAC leads to a significant decrease in PD-L1 expression in tumors. …”
  3. 243

    DataSheet_1_A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells.docx by Yu-Ying Shi (15975992)

    Published 2023
    “…Introduction<p>Our previous research has found that degradation of palmitoyltransferase in tumor cells using a linear peptide PROTAC leads to a significant decrease in PD-L1 expression in tumors. …”
  4. 244
  5. 245

    Nimodipine does not decrease markers of neuritic dystrophy in 5XFAD transgenic mice. by Katherine R. Sadleir (12035242)

    Published 2022
    “…Similarly, BACE1, LAMP1 and LC3B-II/ LC3B-I were also increased in nimodipine-treated 5XFAD compared to nimodipine treated non-transgenic mice, indicating that nimodipine did not decrease the accumulation of these dystrophic neurite marker proteins. …”
  6. 246
  7. 247
  8. 248
  9. 249
  10. 250
  11. 251
  12. 252
  13. 253
  14. 254
  15. 255
  16. 256
  17. 257
  18. 258
  19. 259
  20. 260

    DataSheet_1_Decreased TCF1 and BCL11B expression predicts poor prognosis for patients with chronic lymphocytic leukemia.docx by Taotao Liang (9944552)

    Published 2022
    “…<p>T cell immune dysfunction is a prominent characteristic of chronic lymphocytic leukemia (CLL) and the main cause of failure for immunotherapy and multi-drug resistance. …”